Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Aeglea BioTherapeutics Inc. (AGLE)

9.06   -0.27 (-2.89%) 07-02 16:00
Open: 9.52 Pre. Close: 9.33
High: 9.52 Low: 8.93
Volume: 114,465 Market Cap: 404M
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic and cancer diseases. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme which is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. Its preclinical pipeline products comprise ACN00177, a product candidate for the treatment of homocystinuria; AEB5100, a recombinant human enzyme that degrades plasma cystine and cysteine; AEB2109, an engineered human enzyme that targets the degradation of the amino acid methionine; and AEB3103, a product candidate. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 9.53 - 9.585 9.585 - 9.634
Low: 8.81 - 8.867 8.867 - 8.918
Close: 8.977 - 9.069 9.069 - 9.153

Technical analysis

as of: 2020-07-02 4:27:16 PM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 11.56     One year: 13.29
Support: Support1: 7.50    Support2: 6.24
Resistance: Resistance1: 9.90    Resistance2: 11.38
Pivot: 9.41
Moving Average: MA(5): 9.20     MA(20): 9.20
MA(100): 7.12     MA(250): 7.55
MACD: MACD(12,26): 0.28     Signal(9): 0.39
Stochastic oscillator: %K(14,3): 43.41     %D(3): 44.14
RSI: RSI(14): 50.44
52-week: High: 11.38  Low: 3.50  Change(%): 39.8
Average Vol(K): 3-Month: 32051  10-Days: 67593

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
AGLE has closed above bottom band by 36.3%. Bollinger Bands are 3.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Tue, 30 Jun 2020
Zacks Investment Research Downgrades Aeglea Bio Therapeutics (NASDAQ:AGLE) to Hold - MarketBeat

Mon, 29 Jun 2020
Here's Why Momentum Investors Will Love Aeglea Biotherapeutics (AGLE) - Yahoo Finance

Tue, 23 Jun 2020
Aeglea BioTherapeutics (AGLE) Catches Eye: Stock Jumps 5.1% - Yahoo Finance

Tue, 23 Jun 2020
Is Now the Time to Invest in Aeglea BioTherapeutics Inc. (NASDAQ:AGLE)? - The Oracle Dispatch

Wed, 10 Jun 2020
Has Aeglea BioTherapeutics (AGLE) Outpaced Other Medical Stocks This Year? - Yahoo Finance

Mon, 01 Jun 2020
Aeglea BioTherapeutics to Present at BIO Digital 2020 - GlobeNewswire

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ Global Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 45
Shares Float (M) 33
% Held by Insiders 4.08
% Held by Institutions 57.82
Shares Short (K) 464
Shares Short P. Month (K) 368

Stock Financials

EPS -2.420
EPS Est This Year -2.070
EPS Est Next Year -2.190
Book Value (p.s.) 1.470
Profit Margin
Operating Margin
Return on Assets (ttm) -52.8
Return on Equity (ttm) -100.3
Qtrly Rev. Growth
Gross Profit (p.s.) -1.449
Sales Per Share
EBITDA (p.s.) -1.822
Qtrly Earnings Growth
Operating Cash Flow (M) -72
Levered Free Cash Flow (M) -45

Stock Valuations

PE Ratio -3.74
PEG Ratio
Price to Book value 6.16
Price to Sales
Price to Cash Flow -5.64

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.